Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation

Abstract With the aim of discovering novel IDO1 inhibitors, a combined similarity search and molecular docking approach was employed to the discovery of 32 hit compounds. Testing the screened hit compounds has led to several novel submicromolar inhibitors. Especially for compounds LVS-019 with cyanopyridine scaffold, showed good IDO1 inhibitory activity. To discover more compounds with similar structures to LVS-019, a shape-based model was then generated on the basis of it and the second-round virtual screening was carried out leading to 23 derivatives. Molecular docking studies suggested a possible binding mode of LVS-019, which provides a good starting point for the development of cyanopyridine scaffold compounds as potent IDO1 inhibitor. To improve potency of these hits, we further designed and synthesised another 14 derivatives of LVS-019. Among these compounds, LBJ-10 showed improved potency compared to the hits and displayed comparable potency to the control GDC-0919 analogue. LBJ-10 can serve as ideal leads for further modifications as IDO1 inhibitors for cancer treatment.

[1]  Hans-Georg Rammensee,et al.  IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism , 2008, Cancer Immunology, Immunotherapy.

[2]  M. Bower,et al.  INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology , 2017, ACS medicinal chemistry letters.

[3]  Robert W. Lang,et al.  Synthesis of selectively trifluoromethylated pyridine derivaties as potential antihypertensives , 1988 .

[4]  G. Turcatti,et al.  Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. , 2014, European journal of medicinal chemistry.

[5]  Flavia Castellano,et al.  Immunosuppressive enzymes in the tumor microenvironment , 2017, FEBS letters.

[6]  M. Sono,et al.  1-Methyl-DL-tryptophan, beta-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and beta-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. , 1991, Archives of biochemistry and biophysics.

[7]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[8]  Jürgen Bajorath,et al.  Design and Evaluation of a Molecular Fingerprint Involving the Transformation of Property Descriptor Values into a Binary Classification Scheme , 2003, J. Chem. Inf. Comput. Sci..

[9]  Hao-Ze Huang,et al.  Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening. , 2014, European journal of medicinal chemistry.

[10]  Zhong-Jun Li,et al.  Design, synthesis and biological evaluation of novel naphthoquinone derivatives as IDO1 inhibitors. , 2018, European journal of medicinal chemistry.

[11]  Shan Qian,et al.  IDO as a drug target for cancer immunotherapy: recent developments in IDO inhibitors discovery , 2016 .

[12]  Fang Liu,et al.  Discovery and Design of Tricyclic Scaffolds as Protein Kinase CK2 (CK2) Inhibitors through a Combination of Shape-Based Virtual Screening and Structure-Based Molecular Modification , 2013, J. Chem. Inf. Model..

[13]  C. Sheridan IDO inhibitors move center stage in immuno-oncology , 2015, Nature Biotechnology.

[14]  Alex Avdeef,et al.  Miniaturized Rotating Disk Intrinsic Dissolution Rate Measurement: Effects of Buffer Capacity in Comparisons to Traditional Wood’s Apparatus , 2008, Pharmaceutical Research.

[15]  C. Piccirillo,et al.  Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives , 2011, Clinical Cancer Research.

[16]  Qing Yang,et al.  Oren-gedoku-to and its constituents with therapeutic potential in Alzheimer's disease inhibit indoleamine 2, 3-dioxygenase activity in vitro. , 2010, Journal of Alzheimer's disease : JAD.

[17]  Qing Yang,et al.  Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice. , 2013, Journal of medicinal chemistry.

[18]  Paul Labute,et al.  The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area , 2008, J. Comput. Chem..

[19]  Takashi Otsuki,et al.  Crystal structure of human indoleamine 2,3-dioxygenase: catalytic mechanism of O2 incorporation by a heme-containing dioxygenase. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Klaus R. Liedl,et al.  Minor Groove Binders and Drugs Targeting Proteins Cover Complementary Regions in Chemical Shape Space , 2011, J. Chem. Inf. Model..

[21]  D. Munn,et al.  IDO and tolerance to tumors. , 2004, Trends in molecular medicine.

[22]  Tao Lu,et al.  An Integrated Virtual Screening Approach for VEGFR-2 Inhibitors , 2013, J. Chem. Inf. Model..

[23]  R. W. Lang,et al.  Synthesis of Selectively Trifluoromethylated Pyridine Derivatives as Potential Antihypertensives. , 1988 .

[24]  Kazuo Suzuki,et al.  Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO) , 2011, PloS one.

[25]  Malgorzata N. Drwal,et al.  Combination of ligand- and structure-based methods in virtual screening. , 2013, Drug discovery today. Technologies.

[26]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. , 2007, Cancer research.

[27]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[28]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[29]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[30]  G. Prendergast,et al.  Non-hematopoietic expression of IDO is integrally required for inflammatory tumor promotion , 2010, Cancer Immunology, Immunotherapy.

[31]  P. Scherle,et al.  Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy. , 2009, Current cancer drug targets.

[32]  D. Munn,et al.  Ido expression by dendritic cells: tolerance and tryptophan catabolism , 2004, Nature Reviews Immunology.

[33]  Stewart B Kirton,et al.  Prediction of binding modes for ligands in the cytochromes P450 and other heme‐containing proteins , 2005, Proteins.

[34]  S. Paul,et al.  Nitrobenzofurazan derivatives of N'-hydroxyamidines as potent inhibitors of indoleamine-2,3-dioxygenase 1. , 2016, European journal of medicinal chemistry.

[35]  Jinlei Bian,et al.  Novel naphtho[2,1-d]oxazole-4,5-diones as NQO1 substrates with improved aqueous solubility: Design, synthesis, and in vivo antitumor evaluation. , 2016, Bioorganic & medicinal chemistry.

[36]  Paul L A Popelier,et al.  The hydration of serine: multipole moments versus point charges. , 2014, Physical chemistry chemical physics : PCCP.

[37]  Tetsuya Kohno,et al.  Crystal Structures and Structure-Activity Relationships of Imidazothiazole Derivatives as IDO1 Inhibitors. , 2014, ACS medicinal chemistry letters.

[38]  Su-Ying Wu,et al.  Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1. , 2016, Journal of medicinal chemistry.

[39]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[40]  Simona Distinto,et al.  How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information , 2009, J. Chem. Inf. Model..

[41]  C. Uyttenhove,et al.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase , 2003, Nature Medicine.

[42]  Qian Wang,et al.  Discovery of potent competitive inhibitors of indoleamine 2,3-dioxygenase with in vivo pharmacodynamic activity and efficacy in a mouse melanoma model. , 2009, Journal of medicinal chemistry.

[43]  H. Koblish,et al.  Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.

[44]  Charles L. Brooks,et al.  Detailed analysis of grid‐based molecular docking: A case study of CDOCKER—A CHARMm‐based MD docking algorithm , 2003, J. Comput. Chem..

[45]  S. Kaiser,et al.  Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. , 2017, Journal of medicinal chemistry.

[46]  Olivier Michielin,et al.  Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. , 2015, Journal of medicinal chemistry.

[47]  David J. Freeman,et al.  Reinstalling Antitumor Immunity by Inhibiting Tumor-Derived Immunosuppressive Molecule IDO through RNA Interference1 , 2006, The Journal of Immunology.

[48]  Charles J. Link,et al.  Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. , 2013 .

[49]  Tingjun Hou,et al.  Development and Evaluation of an Integrated Virtual Screening Strategy by Combining Molecular Docking and Pharmacophore Searching Based on Multiple Protein Structures , 2013, J. Chem. Inf. Model..

[50]  Paolo Vicini,et al.  Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors , 2016 .

[51]  O. Hayaishi,et al.  Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. , 1986, The Journal of biological chemistry.

[52]  O. Hayaishi,et al.  Properties and function of indoleamine 2,3-dioxygenase. , 1976, Journal of biochemistry.